['metastatic breast cancer']
['abemaciclib']

        Inclusion Criteria.

          -  Have a diagnosis of Hormone Receptor Positive (HR+), Human Epidermal Growth Factor
             Receptor 2 Negative (HER2-) breast cancer.

          -  Recurrent, locally advanced, unresectable or metastatic breast cancer with disease
             progression following anti-estrogen therapy.

          -  Prior treatment with at least 2 chemotherapy regimens:

               -  At least 1 of these regimens must have been administered in the metastatic
                  setting.

               -  At least 1 of these regimens must have contained a taxane.

               -  No more than 2 prior chemotherapy regimens in the metastatic setting.

          -  Have a performance status (PS) of 0 to 1 on the Eastern Cooperative Oncology Group
             scale.

          -  Have discontinued all previous therapies for cancer.

          -  Have the presence of measureable disease as defined by Response Evaluation Criteria in
             Solid Tumors Version 1.1.

        Exclusion Criteria:

          -  Have either a history of central nervous system (CNS) metastasis or evidence of CNS
             metastasis on the magnetic resonance image of brain obtained at baseline.

          -  Received prior therapy with another cyclin-dependent kinases 4 and 6 (CDK4/6)
             inhibitor.

          -  Have received treatment with a drug that has not received regulatory approval for any
             indication within 14 or 21 days of the initial dose of study drug.

          -  Have had major surgery within 14 days of the initial dose of study drug.

          -  Have a history of any other cancer (except non-melanoma skin cancer or carcinoma
             in-situ of the cervix).
      